BWAY Profile
BrainsWay Ltd. is a leading developer and provider of noninvasive neurostimulation therapies aimed at addressing a range of mental health disorders and neurological conditions. The company specializes in Deep Transcranial Magnetic Stimulation (dTMS) technology, which is designed to treat various mental health issues including major depressive disorder, anxious depression, obsessive-compulsive disorder, and smoking addiction. BrainsWay's platform is also employed in managing bipolar disorder, post-traumatic stress disorder, schizophrenia, and several other psychiatric conditions.
In addition to its mental health applications, BrainsWay’s neurostimulation technology is utilized for a variety of neurological disorders. This includes chronic pain management, multiple sclerosis, post-stroke rehabilitation, and Parkinson’s disease. The company's advanced technology is aimed at offering noninvasive treatment options that can potentially improve patient outcomes across a broad spectrum of conditions.
BrainsWay serves a diverse range of healthcare providers, including doctors, hospitals, and specialized medical centers focused on psychiatry and neurology. By providing its technology to these professionals, BrainsWay aims to enhance treatment options and outcomes for patients with challenging conditions. The company’s platform is designed to integrate seamlessly into existing clinical practices, supporting healthcare providers in delivering innovative care.
Founded in 2003, BrainsWay Ltd. is headquartered in Jerusalem, Israel. The company has expanded its reach internationally, with a presence in the United States, Europe, and other global markets. BrainsWay’s commitment to advancing noninvasive neurostimulation technology underscores its role as a pioneer in the field of mental health and neurological treatment.
|
